Patrick D. Lyden, M.D.
Dr. Patrick D. Lyden is a neurologist who is currently affiliated with Cedars-Sinai Marina del Rey Hospital. He received his medical degree from the Baylor College of Medicine and completed his residency at the University of California, San Diego School of Medicine. The physician has done extensive research on the subject of translational stroke and has published numerous papers on various subjects regarding the science of neurology. His work has been recognized with numerous awards and Dr. Patrick D. Lyden is a member of multiple associations, such as the American Heart Association, the American Neurology Association, and the Society for Neuroscience. In 2020, he joined the faculty of the Keck School of Medicine of USC as a Professor of Physiology and Neuroscience and of Neurology, as well as a Zilkha Scholar within the USC Zilkha Neurogenetic Institute.
As a recognized global leader in stroke therapy, Dr. Patrick D. Lyden led a landmark clinical study in 1995 that resulted in the approval of the first treatment for stroke, which involves the intravenous delivery of engineered protein that breaks down blood clots. The neurologist also played a crucial role in refining the National Institute of Health Stroke Scale, a widely used tool for evaluating the severity of a stroke. He produced and directed training and certification videos about the scale that have been viewed almost 2 million times by health care providers around the world. The co-author of over 350 peer-reviewed papers and book chapters, Dr. Patrick D. Lyden has received research funding from federal agencies constantly for over 30 years. He is advancing a new approach to stroke treatment by using agents that target multiple biochemical pathways at the same time. His studies delve into the toxic effect on brain cells of thrombin, the enzyme that helps the blood clot, as well as the therapeutic possibilities of blocking that enzyme.
Insurance Accepted
- Aetna Choice POS II
- Cigna
- First Health PPO
- Great West PPO
- HealthNet
- Multiplan PPO
- United Healthcare
Languages Spoken
- English
Education & Training
Medical Degree
Baylor College of Medicine
Internship(s)
Mercy Hospital and Medical Center
Residency(ies)
University of California, San Diego School of Medicine
Fellowship(s)
University of California, San Diego School of Medicine
Memberships & Affiliations
American Heart Association
Publications & Media
-
Differential Expression of Vascular Endothelial Growth Factor-A165 Isoforms Between Intracranial Atherosclerosis and Moyamoya Disease.
Jiang, H., Toscano, J.F., Schiraldi, M., Song, S.S., Schlick, K.H., Dumitrascu, O.M., Liou, R., Lyden, P.D., Pan, J., Zhan, R., Saver, J.L., Gonzalez, N.R.
-
Neuron-generated thrombin induces a protective astrocyte response via protease activated receptors.
Rajput, P. S., Lamb, J., Kothari, S., Pereira, B., Soetkamp, D., Wang, Y., Tang, J., Van Eyk, J. E., Mullins, E. S., Lyden, P. D.
-
Differential effects of hypothermia on neurovascular unit determine protective or toxic results: Toward optimized therapeutic hypothermia.
Lyden, P.D., Lamb, J., Kothari, S., Toossi, S., Boitano, P., Rajput, P.S.
-
Acute neuropathological consequences of short-term mechanical ventilation in wild-type and Alzheimer's disease mice.
Lahiri, S., Regis, G.C., Koronyo, Y., Fuchs, D.T., Sheyn, J., Kim, E.H., Mastali, M., Van Eyk, J.E., Rajput, P.S., Lyden, P.D., Black, K.L., Ely, E.W., D Jones, H., Koronyo-Hamaoui, M.
-
Neuroprotection and vasculoprotection using genetically targeted protease-ligands.
Rajput, P.S., Lamb, J.A., Fernández, J.Á., Bai, J., Pereira, B.R., Lei, I.F., Leung, J., Griffin, J.H., Lyden, P.D.
-
β-adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, and inflammatory response after traumatic brain injury.
Ley, E.J., Clond, M.A., Bukur, M., Park, R., Chervonski, M., Dagliyan, G., Margulies, D.R., Lyden, P.D., Conti, P.S., Salim, A.
-
Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH.
Sansing, L.H., Messe, S.R., Cucchiara, B.L., Cohen, S.N., Lyden, P.D., Kasner, S.E.; CHANT Investigators.
-
Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke.
Hemmen, T.M., Lyden, P.D.
-
Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models.
Rajput, P.S., Lyden, P.D., Chen, B., Lamb, J.A., Pereira, B., Lamb, A., Zhao, L., Lei, I.F., Bai, J.
-
Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
Wang, Y., Zhao, Z., Chow, N., Rajput, P.S., Griffin, J.H., Lyden, P.D., Zlokovic, B.V.
-
Concurrent middle cerebral artery occlusion and intra-arterial drug infusion via ipsilateral common carotid artery catheter in the rat.
Van Winkle, J.A., Chen, B., Lei, I.F., Pereira, B., Rajput, P.S., Lyden, P.D.
-
Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models.
Lyden, P., Pereira, B., Chen, B., Zhao, L., Lamb, J., Lei, I.F., Rajput, P.
-
PHLPP1 gene deletion protects the brain from ischemic injury.
Chen, B., Van Winkle, J.A., Lyden, P.D., Brown, J.H., Purcell, N.H.
-
Thrombin activity associated with neuronal damage during acute focal ischemia.
Chen, B., Friedman, B., Whitney, M.A., Winkle, J.A., Lei, I.F., Olson, E.S., Cheng, Q., Pereira, B., Zhao, L., Tsien, R.Y., Lyden, P.D.